Literature DB >> 10190649

Pharmacokinetics of tolbutamide in ethnic Chinese.

A S Gross1, S Bridge, G M Shenfield.   

Abstract

AIMS: Ethnic differences in drug disposition have been described for many drugs. Despite the widespread use of tolbutamide in Asian populations, the pharmacokinetics of tolbutamide, a CYP2C9 substrate, have not been described in ethnic Chinese.
METHODS: The pharmacokinetics of tolbutamide (500 mg orally) were studied in 10 young, healthy volunteers (seven male/three female; age 21-29 years), each of whom had four ethnic Chinese grandparents. Plasma concentrations of tolbutamide were measured for 32 h post-dose by high performance liquid chromatography. The concentrations of hydroxytolbutamide and carboxytolbutamide were also measured in urine for 32 h post-dose. Noncompartmental pharmacokinetic parameters were calculated using standard equations and compared with those previously reported in Caucasian subjects using the Mann-Whitney U test.
RESULTS: Pharmacokinetic parameters in Chinese (mean+/-s.d.) including Cmax (63+/-11 microg ml(-1)), tmax (median 3.3 h; range 1.6-6.0 h), V/F (9.1+/-1.7 l) and t1/2, (9.1 h; harmonic mean) were similar to the values in Caucasians. CL/F (637+/-88 ml h(-1)) was higher in Chinese than Caucasians. The urinary recoveries of hydroxytolbutamide (13+/-1% of dose) and carboxytolbutamide (68+/-5% of dose) and the partial apparent metabolic clearance (0.15+/-0.02 ml min(-1) kg(-1)) in Chinese were comparable with Caucasians.
CONCLUSIONS: The pharmacokinetics of tolbutamide have been described in ethnic Chinese and the disposition is similar to that reported in Caucasians. This study suggests that there is no substantial ethnic difference in the tolbutamide hydroxylase activity of CYP2C9.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190649      PMCID: PMC2014169          DOI: 10.1046/j.1365-2125.1999.00868.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  A screening test for slow metabolisers of tolbutamide.

Authors:  M A Page; J S Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 2.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Differences in plasma binding of drugs between Caucasians and Chinese subjects.

Authors:  H H Zhou; A Adedoyin; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

4.  Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers.

Authors:  M E Veronese; J O Miners; D Randles; D Gregov; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

5.  Sample size calculations for clinical pharmacology studies.

Authors:  P D Stolley; B L Strom
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

6.  Population pharmacokinetics of phenytoin in Singapore Chinese.

Authors:  E Chan; T Y Ti; H S Lee
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Binding of four sulphonamides to human albumin.

Authors:  R Zini; P d'Athis; A Hoareau; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

8.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

9.  Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 10.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

View more
  4 in total

1.  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Authors:  Natacha Lenuzza; Xavier Duval; Grégory Nicolas; Etienne Thévenot; Sylvie Job; Orianne Videau; Céline Narjoz; Marie-Anne Loriot; Philippe Beaune; Laurent Becquemont; France Mentré; Christian Funck-Brentano; Loubna Alavoine; Philippe Arnaud; Marcel Delaforge; Henri Bénech
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-03       Impact factor: 2.441

2.  Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

Authors:  Zoe E Barter; Geoffrey T Tucker; Karen Rowland-Yeo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

3.  Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations.

Authors:  D Sarnobat; R C Moffett; P R Flatt; A I Tarasov
Journal:  J Endocrinol Invest       Date:  2021-06-30       Impact factor: 4.256

Review 4.  Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Authors:  Siu Wai Choi; Cyrus K Ho
Journal:  Redox Rep       Date:  2017-05-17       Impact factor: 4.412

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.